Martine A. Rothblatt, Chairperson and CEO, has filed 1,899 Form 4 transactions across two companies. The cumulative record is heavily weighted toward sales. Total open-market sales reached $832,412,030.04, against open-market purchases of $863,947.35. That is a sell-to-buy ratio of roughly 963 to 1 by dollar value. The recent activity, all in United Therapeutics (UTHR), continues that direction.
Between September 15 and September 17, 2026, Rothblatt filed 23 open-market sales and two option exercises. The sales on September 15 alone totaled $4,765,119.29 across six transactions, the largest being $1,858,019.40. September 16 brought eight sales worth $4,775,172.20, with the top trade at $1,085,271.70. September 17 had nine sales totaling $4,652,580.46, led by a $1,082,720.84 disposition. The two option exercises, both on September 16 and 17, were each valued at $1,118,720 and coded M, meaning mechanical exercises rather than discretionary purchases.
The pattern is consistent. Rothblatt has not made a single open-market purchase in the recent window, and the sales are clustered in UTHR over three consecutive trading days. The dollar values are large, and the frequency is high. The data shows a clear selling bias, with no recent buys to offset it.
AI-assisted summary